CS First Boston Cuts Applera-Applied Biosystems Rating

Analyst Meirav Chovav doesn't think the maker of biotech instruments will meet its targets, and says foreign currency troubles will likely hurt near-term growth

CS First Boston downgraded Applera-Applied Biosystems (ABI ) to hold from buy.

Analyst Meirav Chovav says she's concerned over the biotech instrument maker's ability to deliver on top-line and bottom-line growth targets. She notes her $422 million Q4 revenue estimate and $0.24 EPS estimate are below the company's guidance and consensus, but she's concerned there could still be a downside. She notes the company says its 10%-13% projected revenue growth over the next several quarters may be adversely impacted as major foreign currencies have continued to a decline.

Chovav is concerned about a slowdown in mass spectrometer orders, and continued weakness in the DNA-sequence analysis market. She sees $0.95 2001 EPS, and $1.08 EPS for 2002.

Before it's here, it's on the Bloomberg Terminal.